- Home
- NMRA vs CTNM Comparison
NMRA vs CTNM Comparison
Compare NMRA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- CTNM
- Stock Information
- Founded
- NMRA 2019
- CTNM 2009
- Country
- NMRA United States
- CTNM United States
- Employees
- NMRA N/A
- CTNM N/A
- Industry
- NMRA
- CTNM
- Sector
- NMRA
- CTNM
- Exchange
- NMRA Nasdaq
- CTNM Nasdaq
- Market Cap
- NMRA 291.5M
- CTNM 328.1M
- IPO Year
- NMRA 2023
- CTNM 2024
- Fundamental
- Price
- NMRA $3.01
- CTNM $10.65
- Analyst Decision
- NMRA Buy
- CTNM Strong Buy
- Analyst Count
- NMRA 8
- CTNM 5
- Target Price
- NMRA $7.43
- CTNM $22.20
- AVG Volume (30 Days)
- NMRA 3.0M
- CTNM 92.7K
- Earning Date
- NMRA 11-06-2025
- CTNM 10-30-2025
- Dividend Yield
- NMRA N/A
- CTNM N/A
- EPS Growth
- NMRA N/A
- CTNM N/A
- EPS
- NMRA N/A
- CTNM N/A
- Revenue
- NMRA N/A
- CTNM N/A
- Revenue This Year
- NMRA N/A
- CTNM N/A
- Revenue Next Year
- NMRA N/A
- CTNM N/A
- P/E Ratio
- NMRA N/A
- CTNM N/A
- Revenue Growth
- NMRA N/A
- CTNM N/A
- 52 Week Low
- NMRA $0.61
- CTNM $3.35
- 52 Week High
- NMRA $14.09
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- NMRA 75.77
- CTNM 45.16
- Support Level
- NMRA $2.40
- CTNM $10.36
- Resistance Level
- NMRA $3.25
- CTNM $11.01
- Average True Range (ATR)
- NMRA 0.27
- CTNM 0.68
- MACD
- NMRA 0.11
- CTNM -0.15
- Stochastic Oscillator
- NMRA 84.76
- CTNM 18.08
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.